Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206216291> ?p ?o ?g. }
- W4206216291 endingPage "1661" @default.
- W4206216291 startingPage "1647" @default.
- W4206216291 abstract "The evaluation of the natural history of NASH has been limited. Currently, liver biopsy remains the gold standard in the assessment of NASH. Placebo-controlled trials represent a controlled environment with paired biopsies for the evaluation of NASH. This meta-analysis thus seeks to quantify the change severity of NASH over time, with patients on placebo arms from randomized controlled trials (RCTs) to examine the natural history of NASH.A search was conducted to include NASH RCTs with placebo treatment arms. Primary outcomes were (1) the resolution of NASH without worsening of fibrosis, (2) two-point reduction in NAFLD activity score without worsening of fibrosis, and (3) at least one-point reduction in fibrosis. Generalized linear mix model was used to estimate pooled proportion and mean differences.This meta-analysis of 43 RCTs included 2649 placebo-treated patients. The pooled estimate of NASH resolution and two-point NAFLD activity score reduction without worsening of fibrosis was 11.65% (95% CI: 7.98-16.71) and 21.11% (95% CI: 17.24-25.57). The rate of ≥1 stage reduction and progression of fibrosis was 18.82% (95% CI: 15.65-22.47) and 22.74% (CI: 19.63-26.17), respectively. Older age and African American ethnicity was associated with lower NASH resolution rate in placebo-treated patients.Despite the absence of any pharmacological interventions, a significant proportion of patients in the placebo arm demonstrated improvements in liver histology, highlighting the possibility that NASH is a disease that can not only progress but regress spontaneously over time. Additionally, histologic response in placebo-treated patients is helpful in future design of phase 2B and phase 3 trials." @default.
- W4206216291 created "2022-01-25" @default.
- W4206216291 creator A5004639766 @default.
- W4206216291 creator A5007912393 @default.
- W4206216291 creator A5009193858 @default.
- W4206216291 creator A5012554063 @default.
- W4206216291 creator A5015041967 @default.
- W4206216291 creator A5025459684 @default.
- W4206216291 creator A5025671725 @default.
- W4206216291 creator A5028905834 @default.
- W4206216291 creator A5033456538 @default.
- W4206216291 creator A5033842737 @default.
- W4206216291 creator A5040791928 @default.
- W4206216291 creator A5043846829 @default.
- W4206216291 creator A5044089244 @default.
- W4206216291 creator A5065450421 @default.
- W4206216291 creator A5070639714 @default.
- W4206216291 creator A5073765015 @default.
- W4206216291 creator A5077629563 @default.
- W4206216291 creator A5080623484 @default.
- W4206216291 creator A5085487679 @default.
- W4206216291 creator A5085940065 @default.
- W4206216291 date "2022-01-24" @default.
- W4206216291 modified "2023-10-18" @default.
- W4206216291 title "Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis" @default.
- W4206216291 cites W1530466595 @default.
- W4206216291 cites W1617328014 @default.
- W4206216291 cites W1973401573 @default.
- W4206216291 cites W1976571856 @default.
- W4206216291 cites W1990055069 @default.
- W4206216291 cites W1997425045 @default.
- W4206216291 cites W2019810874 @default.
- W4206216291 cites W2021000378 @default.
- W4206216291 cites W2021738092 @default.
- W4206216291 cites W2022296797 @default.
- W4206216291 cites W2022803835 @default.
- W4206216291 cites W2032506622 @default.
- W4206216291 cites W2034509216 @default.
- W4206216291 cites W2062812115 @default.
- W4206216291 cites W2065655717 @default.
- W4206216291 cites W2069819211 @default.
- W4206216291 cites W2071411038 @default.
- W4206216291 cites W2080725795 @default.
- W4206216291 cites W2086657341 @default.
- W4206216291 cites W2090738619 @default.
- W4206216291 cites W2091106363 @default.
- W4206216291 cites W2097677758 @default.
- W4206216291 cites W2100093159 @default.
- W4206216291 cites W2103156933 @default.
- W4206216291 cites W2106768039 @default.
- W4206216291 cites W2107328434 @default.
- W4206216291 cites W2107453802 @default.
- W4206216291 cites W2114691160 @default.
- W4206216291 cites W2116393673 @default.
- W4206216291 cites W2136145129 @default.
- W4206216291 cites W2137591261 @default.
- W4206216291 cites W2138306815 @default.
- W4206216291 cites W2139112405 @default.
- W4206216291 cites W2155704469 @default.
- W4206216291 cites W2157891776 @default.
- W4206216291 cites W2170892587 @default.
- W4206216291 cites W2215535790 @default.
- W4206216291 cites W2253420963 @default.
- W4206216291 cites W2316193238 @default.
- W4206216291 cites W2413809816 @default.
- W4206216291 cites W2423391616 @default.
- W4206216291 cites W2470709274 @default.
- W4206216291 cites W2472627662 @default.
- W4206216291 cites W2569813586 @default.
- W4206216291 cites W2619337392 @default.
- W4206216291 cites W2622230741 @default.
- W4206216291 cites W2757980641 @default.
- W4206216291 cites W2759630103 @default.
- W4206216291 cites W2770634512 @default.
- W4206216291 cites W2779316037 @default.
- W4206216291 cites W278816506 @default.
- W4206216291 cites W2805142669 @default.
- W4206216291 cites W2808779488 @default.
- W4206216291 cites W2821544409 @default.
- W4206216291 cites W2886443073 @default.
- W4206216291 cites W2930850699 @default.
- W4206216291 cites W2934946727 @default.
- W4206216291 cites W2945803471 @default.
- W4206216291 cites W2973208413 @default.
- W4206216291 cites W2985579744 @default.
- W4206216291 cites W2986883158 @default.
- W4206216291 cites W2991974053 @default.
- W4206216291 cites W2993083975 @default.
- W4206216291 cites W2998643329 @default.
- W4206216291 cites W3000140653 @default.
- W4206216291 cites W3004467589 @default.
- W4206216291 cites W3009821608 @default.
- W4206216291 cites W3009945933 @default.
- W4206216291 cites W3013169226 @default.
- W4206216291 cites W3020176834 @default.
- W4206216291 cites W3020802882 @default.
- W4206216291 cites W3023806627 @default.
- W4206216291 cites W3024628764 @default.